



EUROPEAN HEALTH DATA & EVIDENCE NETWORK

EHDEN

F o u n d a t i o n

EHDEN: From Project to Foundation

Carlos Díaz, SYNAPSE CEO / EHDEN Board member



EHDEN: VISION AND MISSION



Vision

The European Health Data & Evidence Network (EHDEN) aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes and care

Mission

Our mission is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model



EHDEN CONSORTIUM



Start date: 1 Nov 2018
End date: 31 Oct 2024
Duration: 72 months



25 partners



Almost €30 million

Universities, public bodies and research organisations



Academic
coordinator



NICE
National Institute for
Health and Care Excellence



UNIVERSITY OF
OXFORD

EFPIA & Associated partners



EFPIA Lead



Celgene | Bristol Myers Squibb™
Company



Lilly



SME & Mid-sized companies



Non-profit organisations







DATA PARTNER NETWORK [AFTER 7 CALLS]



<https://www.ehdn.eu/datapartners/>




- 4 DP in Sweden**
- MEB KI
 - SWIBREG
 - Gothenborg University
 - Stockholm CREATinine Measurements Project




SMALL MEDIUM ENTERPRISES (SME) NETWORK [AFTER 4 CALLS]

🌐 <https://www.ehdn.eu/business-directory/>



📍 Certified SMEs (n=64)


⬤ Applications (n=143)



VISION AND MISSION

Vision

The EHDEN Foundation aspires to be the trusted key actor in Europe to facilitate and accelerate the generation of high-quality real-world evidence to improve healthcare of patients



Mission


Our mission is to operationalize a new paradigm for the discovery and analysis of health data, building on a large-scale federated network of data sources standardised to the OMOP common data model .

Innovative
Professional
Inclusive
Independent

Values

Trustworthy
Actionable
Efficient
Passionate

EHDEN-F STRUCTURE



GOVERNANCE

Supervisory Board

Scientific Advisory
Board

Executive Board

Working
groups



Prof. Peter R. Rijnbeek
Chair of Board



Prof. Daniel Prieto-Alhambra
Board member



Carlos Diaz
Board member



EHDEN
Foundation staff

Industry Advisory
Board




abbvie



Celgene | Bristol Myers Squibb™
Company



ENGAGEMENT WITH DATA PARTNERS



MoU

Signed with 105 DPs




Framework Agreement

Signed with 61 DPs



Work Orders

Signed by 33 DPs



KEY RESEARCH ACTIVITIES

Advisory	Studies	Research Programmes	Training
Data landscaping	Disease Epidemiology	Neuroscience	Study-a-thon
Feasibility	Drug Utilisation	<i>Other</i>	Online training
Study Design	Drug Safety/Effectiveness	<i>Other</i>	On-site training

Services



	Completed	Ongoing	In Negotiation
Data landscaping	3		1
Feasibility	3	2	1
Studies			1
Research Programmes		1	1



Testing, improving, and co-creating
Guidelines for Real World Evidence
Generation in Europe

- ✓ First IHI Project
- ✓ 29 partners
- ✓ 5 years
- ✓ EHDEN Foundation role to organise DP network involvement

<https://ihi-greg.eu/>

The overarching aim of GREG is to generate, pilot test, and disseminate evidence-based guidance and tools for the use of RWE to inform the development and evaluation of medicines, medical devices, and drug device combinations to support and guide regulatory and HTA decision making.



Thank you!



www.ehdn.eu



@IMI_EHDEN



IMI_EHDEN



github.com/EHDEN